Consolidated Statements of Equity - USD ($) shares in Thousands, $ in Thousands	Total	Adoption of accounting standard	Total Caladrius Biosciences, Inc. Stockholders' Equity	Total Caladrius Biosciences, Inc. Stockholders' Equity Adoption of accounting standard	Series B Convertible Preferred Stock	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Accumulated Deficit Adoption of accounting standard	Treasury Stock	Non- Controlling Interest in Subsidiary
Beginning Balance (shares) at Dec. 31, 2018					10	9,866
Beginning Balance at Dec. 31, 2018	$ 37,454	$ (62)	$ 37,726	$ (62)	$ 0	$ 10	$ 436,433	$ (32)	$ (397,977)	$ (62)	$ (708)	$ (272)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(4,365)		(4,367)						(4,367)			2
Unrealized gain on marketable securities	14		14					14
Share-based compensation (in shares)						96
Share-based compensation	417		417				417
Net proceeds from issuance of common stock (in shares)						431
Net proceeds from issuance of common stock	1,000		1,000				1,000
Ending Balance (shares) at Mar. 31, 2019					10	10,393
Ending Balance at Mar. 31, 2019	34,458		34,728		$ 0	$ 10	437,850	(18)	(402,406)		(708)	(270)
Beginning Balance (shares) at Dec. 31, 2019					10	10,529
Beginning Balance at Dec. 31, 2019	20,553		20,816		$ 0	$ 11	438,911	2	(417,400)		(708)	(263)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(3,986)		(3,990)						(3,990)			4
Unrealized gain on marketable securities	(2)		(2)					(2)
Share-based compensation (in shares)						110
Share-based compensation	419		419				419
Ending Balance (shares) at Mar. 31, 2020					10	10,639
Ending Balance at Mar. 31, 2020	$ 16,984		$ 17,243		$ 0	$ 11	$ 439,330	$ 0	$ (421,390)		$ (708)	$ (259)